Navigant Acquires Substantially All of the Assets of Quorum Consulting

Expanding its Life Sciences Practice and Overall Capabilities in Market Access

Navigant (NYSE: NCI) today announced it acquired substantially all of the assets of Quorum Consulting, Inc., a San Francisco-based consulting firm that provides commercial readiness, reimbursement strategy, and market access services to medical technology, pharmaceutical/biotechnology, and laboratory diagnostics clients. 

The addition of the experienced Quorum professionals, as well as the firm’s methodologies, expands Navigant’s capabilities in the life sciences industry. Quorum helps develop clinical evidence and outcomes data to support payer coverage policies and product adoption.  Quorum’s services to clients include strategic product planning, reimbursement policy and government affairs, health economics and outcomes research, and market access programs.

“In today’s life sciences industry, it is critical that companies understand the conditions necessary to optimize access. Quorum has created a proven methodology to help clients achieve greater market access for their innovations,” said Eduardo Schur, managing director and global life sciences practice leader, Navigant. “Quorum has been highly successful and we are excited by the opportunity to develop and expand their capabilities and service offerings into other areas of our life sciences and healthcare practices.”

The Quorum team, including founder and CEO Kuo Bianchini Tong, will join the life sciences practice within Navigant’s Healthcare segment.

“Data-driven decision-making and strategic planning pertaining to reimbursement, health economics and outcomes research, and market access is vital to the success of life sciences companies,” Tong said. “The addition of Quorum’s offerings to Navigant’s deep industry expertise will help enable our clients to capitalize on their market opportunity.”

Back to top